Projects per year
Personal profile
Research interests
Dr. Thonhoff’s research focuses on the role of regulatory T cells (Tregs) in ALS. The loss of Treg function is associated with acceleration of disease progression in ALS. Dr. Thonhoff is exploring the mechanisms through which Treg function is lost in ALS and potential therapies aimed to enhance the neuroprotective function of Tregs. He is also investigating the use of autologous Treg infusions as a therapy for patients with ALS. In addition, he is involved in several clinical trials investigating novel treatments for patients with Myasthenia Gravis, Myotonic Dystrophy and CIDP.
Research Area Keywords
- Neurosciences
- Immunobiology & Inflammation
Free-text keywords
- Neuromuscular disorders
- Neurodegenerative diseases
- Amyotrophic Lateral Sclerosis (ALS)
- Myasthenia Gravis
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Muscular Dystrophy
- Cellular and genetic therapies
- Neuroinflammation
Fingerprint
Dive into the research topics where Jason R. Thonhoff is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Home Visits are the Answer for Homebound Patients with Amyotrophic Lateral Sclerosis
Greene, E. P. & Thonhoff, J. R.
5/9/24 → …
Project: Clinical Trial
-
A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis
Thonhoff, J. R., Beers, D. R., Zhao, W., Faridar, A., Thome, A., Wen, S., Zhang, A., Wang, J. & Appel, S. H., 2024, In: Frontiers in Neurology. 15, p. 1415106 1415106.Research output: Contribution to journal › Article › peer-review
Open Access -
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
MG0003 study team, May 2023, In: The Lancet Neurology. 22, 5, p. 383-394 12 p.Research output: Contribution to journal › Article › peer-review
71 Scopus citations -
Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development
for the Healey ALS Platform Trial Study Group, HEALEY ALS Platform Trial Study Group, Biostatisticians, Investigators, Clinical Operations Team & Medical Monitors, Feb 1 2022, In: Annals of Neurology. 91, 2, p. 165-175 11 p.Research output: Contribution to journal › Article › peer-review
Open Access46 Scopus citations -
Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral Sclerosis
Thonhoff, J. R., Berry, J. D., Macklin, E. A., Beers, D. R., Mendoza, P. A., Zhao, W., Thome, A. D., Triolo, F., Moon, J. J., Paganoni, S., Cudkowicz, M. & Appel, S. H., Nov 29 2022, In: Neurology: Neuroimmunology and NeuroInflammation. 9, 6, e200019.Research output: Contribution to journal › Article › peer-review
Open Access20 Scopus citations -
Extracellular Vesicles Derived From Ex Vivo Expanded Regulatory T Cells Modulate In Vitro and In Vivo Inflammation
Thome, A. D., Thonhoff, J. R., Zhao, W., Faridar, A., Wang, J., Beers, D. R. & Appel, S. H., Jun 22 2022, In: Frontiers in immunology. 13, p. 875825 875825.Research output: Contribution to journal › Article › peer-review
Open Access14 Scopus citations